Progenics Urges Shareholders to Vote Today “FOR” the Highly Qualified Director Candidates on the WHITE Proxy Card
08 juil. 2019 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
Progenics Pharmaceuticals Strengthens Management Team with Appointment of Huw Jones as Vice President, Commercial
08 juil. 2019 07h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Progenics Shareholders Vote “FOR” ALL of Progenics’ Director Nominees
01 juil. 2019 07h00 HE
|
Progenics Pharmaceuticals Inc.
Glass Lewis Believes Velan’s “Fundamental Operational and Corporate Governance Case Fails to Bear Fruit” Glass Lewis Agrees the Current Settlement Offer is Fair and “Would Grant Velan Direct Board...
Progenics Reiterates Targeted Directors’ Indispensable Experience and Leadership Critical to the Company’s Long-Term Success
28 juin 2019 10h30 HE
|
Progenics Pharmaceuticals Inc.
Comments on ISS Report Urges Shareholders to Vote “FOR” All of the Company’s Qualified Directors on the WHITE Proxy Card NEW YORK, June 28, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals,...
Progenics Pharmaceuticals Details Recent Good Faith Efforts to Settle with Velan Capital
27 juin 2019 21h00 HE
|
Progenics Pharmaceuticals Inc.
Velan Rebuffed Very Reasonable Offer that Included a One Year Standstill, Designating Two New Independent Directors and an Incumbent Director Not Standing for Re-election in 2020 Despite Progenics’...
Data Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting Highlights Potential of Progenics’ PSMA-Targeted Imaging Agent, PyL, in Detecting Prostate Cancer
25 juin 2019 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, June 25, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
Independent Readers Using Progenics’ PSMA AI Demonstrated a Statistically Significant Improvement of Accuracy, Speed, and Reproducibility Over Readers Without PSMA AI
24 juin 2019 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
Progenics Pharmaceuticals Files Supplemental Investor Presentation Rebutting Velan’s Latest Inaccurate Claims
24 juin 2019 08h00 HE
|
Progenics Pharmaceuticals Inc.
Board has Positioned Progenics to Maximize Value as a Result of Proactive and Deliberate Strategy Velan’s Baseless Criticisms about the Development of AZEDRA and 1095 Reveal a Fundamental Lack of...
Progenics Pharmaceuticals to Initiate a Basket Trial by Year End to Support an Expanded Label for AZEDRA® (iobenguane I 131) in Multiple MIBG Avid Neuroendocrine Tumors
20 juin 2019 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, June 20, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial...
Progenics to Mail Letter to Shareholders
19 juin 2019 08h30 HE
|
Progenics Pharmaceuticals Inc.
Highlights Velan’s Faulty Assertions and Ongoing Efforts to Mislead Progenics Shareholders Urges Shareholders to Vote “For” All of Company’s Directors on the WHITE Proxy Card NEW YORK, June 19,...